Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study

BMC Infect Dis. 2015 Jul 22:15:277. doi: 10.1186/s12879-015-1023-8.

Abstract

Background: This study aimed to investigate the rate of fluconazole-non-susceptible Cryptococcus neoformans in Southern Taiwan for the period 2001-2012 and analyze the risk factors for acquiring it among patients with invasive cryptococcosis.

Methods: All enrolled strains were isolated from blood or cerebrospinal fluid samples of the included patients. If a patient had multiple positive results for C. neoformans, only the first instance was enrolled. Susceptibility testing was performed using the Clinical and Laboratory Standards Institutes M27-A3 broth micro-dilution method. The MIC interpretative criteria for susceptibility to fluconazole were ≤ 8 μg/ml. A total of 89 patients were included. Patients (n = 59) infected by fluconazole-susceptible strains were compared with those (n = 30) infected by non-susceptible strains. The patients' demographic and clinical characteristics were analyzed.

Results: The rate of fluconazole-non-susceptible C. neoformans in the study period significantly increased over time (p < 0.001). The C. neoformans isolated in 2011-2012 (odds ratio: 10.68; 95 % confidence interval: 2.87-39.74; p < 0.001) was an independent predictive factor for the acquisition of fluconazole-non-susceptible C. neoformans.

Conclusions: The rate of fluconazole-non-susceptible C. neoformans has significantly increased recently. Continuous and large-scale anti-fungal susceptibility tests for C. neoformans are warranted to confirm this trend.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use
  • Cerebrospinal Fluid / microbiology
  • Cryptococcosis / drug therapy
  • Cryptococcosis / microbiology*
  • Cryptococcus neoformans / drug effects*
  • Cryptococcus neoformans / isolation & purification
  • Drug Resistance, Bacterial / drug effects
  • Female
  • Fluconazole / pharmacology*
  • Fluconazole / therapeutic use
  • Humans
  • Longitudinal Studies
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Risk Factors
  • Serotyping

Substances

  • Antifungal Agents
  • Fluconazole